Business Standard

Thursday, December 19, 2024 | 09:25 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla dips 7% after Pithampur unit receives 8 USFDA observations

The company said it will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Cipla dips 7% after Pithampur unit receives 8 USFDA observations
Premium

Deepak Korgoankar Mumbai
Shares of Cipla dipped 7 per cent to Rs 956.20 on the BSE in Monday’s intra-day trade after the company said that the United States Food and Drug Administration (USFDA) issued Form 483 with 8 observations after the inspection of its Pithampur manufacturing facilities.

USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility from 6th - 17th February, 2023, Cipla said in an exchange filing.

On conclusion of the inspection, the company has received 8 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in